Eurofins Genoma Group

Eurofins Genoma Group

Studi medici

PAST PRESENT FUTURE

Chi siamo

Eurofins Genoma Italia è riconosciuta a livello internazionale per la sua leadership nella diagnostica molecolare e per il suo lavoro pionieristico nella diagnosi prenatale e nella genetica molecolare. In qualità di pioniere nei test genetici, Eurofins Genoma rappresenta il Laboratorio più grande in Italia e uno dei laboratori specializzati più grandi al mondo che fornisce servizi di test genetici. Eurofins Genoma fa parte di un gruppo internazionale, Eurofins, che fornisce servizi e soluzioni diagnostiche avanzate con un forte impegno nella ricerca, tradotta nella volontà di favorire e migliorare i processi diagnostici oggi esistenti, sviluppando nuovi prodotti e servizi nel settore biotecnologico, contribuendo al passaggio dalla medicina curativa a quella predittiva. In oltre 30 anni, Eurofins è passata da un laboratorio a Nantes, in Francia, a oltre 50.000 dipendenti attraverso una rete di 900 società indipendenti in oltre 50 paesi che gestiscono più di 800 laboratori. Eurofins offre un portafoglio di oltre 200.000 metodi analitici per valutare la sicurezza, l'identità, la composizione, l'autenticità, l'origine, la tracciabilità e la purezza di sostanze e prodotti biologici. Nel 2020, Eurofins ha generato ricavi totali per 5,4 miliardi di euro ed è stato tra i titoli con le migliori performance in Europa negli ultimi 20 anni.

Settore
Studi medici
Dimensioni dell’azienda
51-200 dipendenti
Sede principale
Roma
Tipo
Società privata non quotata
Settori di competenza
Diagnosi Prenatale, Genetica forense e test di paternità, Diagnosi Genetica Preimpianto (PGD), Nutrigenetica, Farmacogenetica e Genetica della riproduzione

Località

Dipendenti presso Eurofins Genoma Group

Aggiornamenti

  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    Eurofins Genoma has been the first company to introduce NIPT (Non-Invasive Prenatal Testing) in Italy. For over 10 years, our mission has been focusing on continuous research and development to provide increasingly accurate and efficient screening. To achieve this, in addition to using cutting-edge technology, we employ advanced bioinformatic tools, built on the extensive experience in our laboratories. 🧬 The data derived from the analysis of over 70,000 women have allowed us to optimize the performance of our systems, enhancing the precision and reliability of our results. Each report undergoes a second validation by a team of specialists, including biologists and geneticists, to ensure the reliability and completeness of the information, addressing any limitations of the technology. Prenatalsafe has been supporting every expectant mother for over 10 years.

    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 is the main tool in the fight against cancer. Awareness of breast cancer is crucial for early diagnosis. According to the National Cancer Institute (NCI), it is estimated that 5-10% of breast cancer cases may be associated with inherited genetic mutations. However, recent studies indicate that the overall hereditary component, including less well-known family factors, may reach 𝐮𝐩 𝐭𝐨 𝟏𝟓-𝟐𝟎%. The American Cancer Society emphasizes the importance of mutations in the BRCA1 and BRCA2 genes as significant risk factors for the development of breast cancer. In cases of 𝐟𝐚𝐦𝐢𝐥𝐲 𝐡𝐢𝐬𝐭𝐨𝐫𝐲 of breast cancer, it is essential to consider 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐜𝐨𝐮𝐧𝐬𝐞𝐥𝐢𝐧𝐠, as these resources can provide valuable information for risk management and developing 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐩𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐦𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬. #BreastCancerAwareness #BreastCancer #OncologicalPrevention

    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    Join us at the XXII National A.G.E.O. Congress 2024! It will be a unique opportunity to foster dialogue among participants while exploring the latest innovations in the health sector. The congress will cover significant topics such as Artificial Intelligence, Robotic Surgery, and Tissue Regeneration. We are pleased to share ideas and discover together the milestones we are achieving in our field. We look forward to welcoming many of you for a stimulating and enriching exchange! #EurofinsGenoma #AGEO2024 #Innovation #ArtificialIntelligence #RoboticSurgery #TissueRegeneration"

    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    🌍✨ Today we celebrate World Food Day, an opportunity to reflect on the importance of healthy and conscious nutrition. In this context, it's crucial to recognize the role that genetics plays in our well-being, helping us understand how our bodies react to different nutrients. Genetics determines our metabolic predispositions, food intolerances, and the ability to absorb certain nutrients. Personalizing our diet based on genetic profiles can optimize health, enhance well-being, and prevent diseases. Eurofins Genoma aims to promote greater food awareness and help people live their best lives. Because every meal should be a step towards well-being! 🥗💚 #WorldFoodDay #Nutrition #FoodIntolerances #Wellness #Nutrinext #EubiomeGut

    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    We are pleased to present the poster that was accepted and published at the National Congress of the SIM - Società Italiana di Microbiologia, held in Pavia from 8 to 11 September. 🔬The poster, produced in collaboration with UniCamillus International Medical University, presented a case study of approximately 200 patients tested by Eurofins Genoma for the vaginal microbiome. 🌟 Always excited to share our results with you and contribute to research! #Microbiology #Research #Microbiome

    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
      + 2
  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    🧬 The role of the Gut Microbiome in Cancer Treatment Response 📊 Recent research continues to unveil the pivotal role that the gut microbiome plays in influencing human health, particularly by shaping systemic immune responses. Dysbiosis, or imbalance in gut flora, has been linked to various diseases such as inflammatory bowel disease, neurological disorders, and liver disease. But what’s even more groundbreaking is the emerging connection between the gut microbiome and cancer immunotherapy. New mechanistic studies and clinical trials have shown that the gut microbiota can directly modulate the response to immune checkpoint inhibitors (ICIs), potentially overcoming resistance to these therapies and improving patient outcomes. 📑 This recent review highlights the exciting progress being made in this area, offering fresh insights into how gut microbiome-based therapies may soon revolutionize cancer treatment by enhancing the efficacy of ICI immunotherapy. 💡 The microbiome is not just a bystander in our health—it could be a key player in future cancer therapies. 🔎 Read the article: https://lnkd.in/dvWEPqpP #Microbiome #CancerResearch #Immunotherapy #CancerTreatment #GutHealth #InnovationInMedicine #PrecisionMedicine #ClinicalResearch

    The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect

    The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect

    sciencedirect.com

  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    Each person has a unique bacterial fingerprint, a distinctive profile of microorganisms that varies from individual to individual, while still containing common species. Three main variants, known as ENTEROTYPES, have been identified: 🔹 ENTEROTYPE B: characterised by a higher abundance of Firmicutes, typical of those with a diet rich in fats and proteins. 🔹 ENTEROTYPE P: characterised by a greater abundance of Prevotella, common in individuals with a carbohydrate-dominant diet. 🔹 ENTEROTYPE R: marked by a higher presence of Bacteroidetes, typical of those who have a varied diet with a high daily fibre intake. 💡 ENTEROTYPES are influenced by the microenvironment and lifestyle, meaning they can be modified. Some studies have shown that belonging to a particular enterotype can affect responses to therapies, such as oncological treatments. For this reason, identifying them is clinically significant. #genetictest #microbiota #gutmicrobiota #intestinalemicrobiota #enterotype

    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Eurofins Genoma Group, immagine

    14.952 follower

    🏆 Nobel Prize in Physiology or Medicine 2024 🏆 Congratulations to Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNA (miRNA), a revolution that continues to unlock new frontiers in biomedical research. 🔎 The Eurofins Genoma research team has recently explored the potential of miRNA. We conducted a study analysing the mutational status of TP53 and the expression of circulating microRNA to assess the risk of locoregional recurrence. Serial biomarker monitoring allowed us to identify high-risk patients, paving the way for precise tracking of disease evolution and possible intensification of post-operative treatment. 👉 To learn more, read the article "Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer" https://lnkd.in/dHZZhqeY #NobelPrize #microRNA #biomedicalresearch #precisionmedicine #innovation

    • Nessuna descrizione alternativa per questa immagine

Pagine simili

Sfoglia le offerte di lavoro